TP53 and cancer: Based on BECN1 and BRCA1 CNV (diploid versus shallow deletion), it is apparent that patients bearing an ovarian cancer with shallow deletion of the two tumor suppressor genes have a significant better prognosis, i.e., overall and disease-free survival (p = 0.0105 and p = 0.0364) than the patients bearing a cancer with diploid CNV, independently of the TP53 status (Figure 4A,B).